26 Results for "

cyclin-dependent kinase activity

" in MedChemExpress (MCE) Product Catalog:
Products (26)

26 Results for "cyclin-dependent kinase activity" in MCE Product Catalog:

41
41 Publications Verification
Cat. No.: HY-12214A
CAS No.: 1263373-43-8
Purity:  99.60%
Target:  

CDK Apoptosis

Research Areas:  

Cancer

NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC50 of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC50 values of 0.584 μM, 0.706 μM, and 0.605 μM, respectively. NVP-2 induces cell apoptosis.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-114177
CAS No.: 2185857-97-8
Purity:  99.91%
Synonyms: PF-06873600
Target:  

CDK

Research Areas:  

Cancer

PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-16559
CAS No.: 920113-03-7
Synonyms: P276-00
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N9561
CAS No.: 155179-21-8
Vanicoside B is a phenylpropanoyl sucrose derivative, can be isolated from the herb Persicaria dissitiflora. Vanicoside B targets cyclin-dependent kinase 8 (CDK8) and exhibits anti-tumor activity. The potential mechanism is Vanicoside B blocks CDK8-mediated signaling pathways and decreases the expression of epithelial-mesenchymal transition proteins, so that it leads to cell cycle arrest and apoptosis .
loading...
    loading...
Cat. No.: HY-139254
CAS No.: 667463-82-3
Purity:  99.10%
Synonyms: IDR3O; I3O
Target:  

CDK GSK-3 JNK Wnt

Research Areas:  

Neurological Disease

Indirubin-3′-oxime (IDR3O), a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase(GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes .
loading...
    loading...
Cat. No.: HY-112358
CAS No.: 222036-17-1
Purity:  99.04%
Target:  

CDK

Research Areas:  

Neurological Disease Cancer

GW8510 is a potent cyclin-dependent kinase-2 (CDK2) inhibitor. GW8510 is also a ribonucleotide reductase M2 (RRM2) inhibitor. GW8510 exhibits neuroprotective and anticancer activities .
loading...
    loading...
Cat. No.: HY-115565
CAS No.: 190653-73-7
Target:  

CDK Apoptosis

Research Areas:  

Cancer

CGP-74514 (Compound 13) is a highly selective cyclin-dependent kinase 1 (CDK1) inhibitor (IC50=25 nM). CGP-74514 inhibits CDK1/cyclin B complex activity, arrests the cell cycle at G2/M phase and induces tumor cell apoptosis. CGP-74514 is promising for research of bladder cancer .
loading...
    loading...
Cat. No.: HY-151071
CAS No.: 2488761-18-6
Research Areas:  

Cancer

TMX-3013 is a CDK inhibitor capable of inhibiting the activity of CDK1, CDK2, CDK4, CDK5, and CDK6, with IC50 values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM, respectively. TMX-3013 can be used as a target protein ligand, conjugated with the PROTAC linker and the CRBN ligand Thalidomide (HY-14658) for the synthesis of PROTAC TMX-2138 (HY-164906). TMX-3013 can also act as an effector ligand, binding to target proteins HaloTag or FKBP, and can be used in the synthesis of regulated induced proximity targeting chimeras (RIPTACs) .
loading...
    loading...
Cat. No.: HY-139342
CAS No.: 2326428-25-3
Purity:  98.87%
Target:  

CDK

Research Areas:  

Cancer

CDK7-IN-4 (compound I) is a potent CDK7 (Cyclin-dependent kinase 7) inhibitor. CDK7-IN-4 shows anticancer activity. CDK7-IN-4 inhibits the in vitro growth of cancer cell lines from a variety of histologies including colon , breast , lung , ovary and stomach , in a dose dependent manner .
loading...
    loading...
Cat. No.: HY-146213
CAS No.: 2445205-24-1
Target:  

CDK

Research Areas:  

Cancer

CDK4/6-IN-12 is a potent cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. CDK4/6-IN-12 has enzymatic inhibitory activity for CDK4 and CDK6 with IC50 of 592.3 nM and 3090 nM, respectively. CDK4/6-IN-12 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-118976
CAS No.: 481724-82-7
Synonyms: CGP-74514A
Target:  

CDK Apoptosis

Research Areas:  

Cancer

CGP-74514 hydrochloride is a highly selective cyclin-dependent kinase 1 (CDK1) inhibitor (IC50: 25 nM). CGP-74514 hydrochloride inhibits CDK1/cyclin B complex activity, arrests the cell cycle at G2/M phase and induces tumor cell apoptosis. CGP-74514 hydrochloride is promising for research of bladder cancer .
loading...
    loading...
Cat. No.: HY-16559A
CAS No.: 920113-02-6
Synonyms: P276-00 free base
Target:  

CDK

Research Areas:  

Cancer

Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib shows antitumor activity on cisplatin-resistant cells .
loading...
    loading...
Cat. No.: HY-178007
CAS No.: 3099145-52-2
Target:  

CDK

Research Areas:  

Cancer

CDK2 degrader 8 is a selective cyclin-dependent kinase 2 (CDK2) degrader. CDK2 degrader 8 can be used in studies related to CDK2 degradation and HR + HER2 - breast cancer .
loading...
    loading...
Cat. No.: HY-114248
CAS No.: 1459216-10-4
Target:  

CDK

Research Areas:  

Cancer

AGM-130 is a cyclin-dependent kinase (CDK) inhibitor. AGM-130 exhibits antitumor activity .
loading...
    loading...
Cat. No.: HY-E70675
Target:  

CDK

Research Areas:  

Cancer

CDK20 is a major controller of cell cycle checkpoints, which regulate cell growth and proliferation and perform a role in the development of many malignancies. CDK20 is thought to have Cyclin-dependent activating kinase (CAK) activity for CDK2 when it is complexed with Cyclin H. CDK20/CycH Recombinant Human Active Protein Kinase can be used to study the function of CDK20/CycH .
loading...
    loading...
Cat. No.: HY-110359
Target:  

CDK Apoptosis

Research Areas:  

Cancer

CGP-74514 dihydrochloride is a highly selective cyclin-dependent kinase 1 (CDK1) inhibitor (IC50=25 nM). CGP-74514 dihydrochloride inhibits CDK1/cyclin B complex activity, arrests the cell cycle at G2/M phase and induces tumor cell apoptosis. CGP-74514 dihydrochloride is promising for research of bladder cancer .
loading...
    loading...
Cat. No.: HY-111932
CAS No.: 244021-67-8
Target:  

CDK GSK-3

Research Areas:  

Cancer

Indirubin-5-sulfonate is a cyclin-dependent kinase (CDK) inhibitor, with IC50 values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively . Indirubin-5-sulfonate also shows inhibitory activity against GSK-3β .
loading...
    loading...
Cat. No.: HY-178350
Research Areas:  

Cancer

MFDCH016 is a potent HDAC1/6 (IC50 = 38/59 nM) and CDK4/6 (IC50 = 680/720 nM) inhibitor. MFDCH016 induces apoptosis and cell cycle arrest in G2/M and G0/G1 phases in MCF-7 cells. MFDCH016 can modulate the HDAC-p21-CDK signaling pathway, increasing the levels of acetylated H3 and p21. MFDCH016 can be used for the study of breast cancer .
loading...
    loading...
Cat. No.: HY-169344
CAS No.: 2943043-62-5
Target:  

CDK

Research Areas:  

Cancer

CDK7-IN-31 (compound 13) is a potent and orally active cyclin-dependent kinase 7 (CDK7) inhibitor with a Kd value of 0.18 nM. CDK7-IN-31 shows anticancer activity .
loading...
    loading...
Cat. No.: HY-E70676
Target:  

CDK

Research Areas:  

Cancer

CDK20 is a major controller of cell cycle checkpoints, which regulate cell growth and proliferation and perform a role in the development of many malignancies. CDK20 is thought to have Cyclin-dependent activating kinase (CAK) activity for CDK2 when it is complexed with Cyclin H. CDK20/CycT1 Recombinant Human Active Protein Kinase is an ortholog of CDK20 .
loading...
    loading...